PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
0.15%
Cash & equivalents yoy growth below half of AVXL's 107.70%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
No Data
No Data available this quarter, please select a different quarter.
0.15%
Below half of AVXL's 107.70%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.11%
Below half of AVXL's 99.13%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.73%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.07%
Both AVXL and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
0.03%
Below half of AVXL's 99.13%. Michael Burry sees a potential red flag for stagnation or capital shortage.
10.13%
50-75% of AVXL's 14.18%. Bruce Berkowitz notes the company is paying suppliers faster or not stretching terms as competitor does.
-6.71%
Higher Short-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-10.13%
1.25-1.5x AVXL's -8.89%. Bruce Berkowitz checks if there's a competitive advantage in forward billing.
6.71%
Higher Other Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
8.18%
Less than half of AVXL's 19.45%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-95.12%
Similar yoy to AVXL's -100.00%. Walter Schloss sees parallel expansions in long-term liabilities.
No Data
No Data available this quarter, please select a different quarter.
6.04%
Less than half of AVXL's 19.45%. David Dodd sees far fewer liability expansions relative to competitor.
4.76%
50-75% of AVXL's 7.31%. Bruce Berkowitz notes minimal new equity relative to competitor.
-2.66%
Below half AVXL's -5.79%. Michael Burry suspects major net losses or high dividends vs. competitor.
100.00%
Less than half of AVXL's -100.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-0.27%
Below half AVXL's 107.29%. Michael Burry sees potential underperformance in building shareholder capital.
0.03%
Below half AVXL's 99.13%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-20.42%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
-0.28%
Less than half of AVXL's -107.70%. David Dodd sees better deleveraging or stronger cash buildup than competitor.